Safety study of BALFAXAR vs. Kcentra for urgent blood thinner reversal
Part of Blood & lymphatic clinical trials.
This study compares the safety of two medications, BALFAXAR and Kcentra, used to quickly reverse the effects of blood thinners (like warfarin) in people who need urgent surgery or a procedure. It helps doctors understand which option may be safer for patients in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently taking a vitamin K antagonist (a blood thinner like warfarin).
- You have received a 4-factor prothrombin complex concentrate (such as BALFAXAR or Kcentra) within 48 hours before an urgent surgery or procedure.
- You have not had a blood clot (thromboembolic event) in the last 3 months.
- Your procedure is urgent (not planned ahead of time).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to safely manage your blood thinner (DOAC) around the time of a planned, high-bleed-risk surgery or procedure involving a spinal needle. The goal is to find the best way to stop and restart your medication to prevent bleeding and clotting problems.
This Phase 3 study tests TAK-330, a reversal (blocking) medicine, to reduce bleeding risk during urgent surgery for adults taking Factor Xa inhibitors like rivaroxaban, apixaban, or edoxaban. It’s for situations where surgery can’t wait and doctors need a fast way to restore normal clotting.
This trial tests a drug called VMX-C001 to quickly reverse the effects of certain blood thinners (Factor Xa inhibitors) in people who need urgent surgery with a high risk of bleeding. It compares VMX-C001 to standard care to see which is more effective at helping blood clot normally.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
Hear when a new Vitamin K-Dependent Coagulation Defect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.